Developing an innovative treatment for Cognitive Impairment

You are here


More than 21 million people worldwide live with schizophrenia, a severe cerebral disorder that causes auditory and visual hallucinations and paranoid delusions and affects the way people manage emotions and relate with others. There are three subtypes of symptoms: positive (visual and auditory senses are affected), negative (lower social interaction), and cognitive impairment (executive function disorders, memory and attention).

Current antipsychotic drugs address mainly the positive symptoms, but the negative symptoms and cognitive impairment still require suitable pharmacological approaches and are thus an unmet medical need. Around 75% of patients with schizophrenia suffer from Cognitive Impairment Associated with Schizophrenia (CIAS).

Parkinson's Disease is the second most common neurodegenerative disease with an estimated prevalence of 1.43% in people older than 60. Parkinson's disease incidence numbers are expected to increase in countries with progressive aging population. Symptomatology includes motor-related features (such as tremor or bradykinesia) and non-motor symptoms (such as cognitive impairment). Cognitive Impairment features appear in 30% of people suffering Parkinson's, without any pharmacological treatment available.

Iproteos’ lead candidate is a first-in-class drug for the treatment of Cognitive Symptoms in Schizophrenia and Parkinson's disease through a novel mechanism of action (MoA). The compound is an orally available, potent and selective small molecule with a novel MoA and with well established efficacy in animal models. It has been recognized to be extremely safe in the GLP toxicology assays conducted. The program will enter into Phase I studies in 2019.